Table 1 Baseline descriptive statistics.

From: The impact of ultra-high-density mapping on long-term outcome after catheter ablation of ventricular tachycardia

 

Total (n = 122)

Ultra-high-density mapping (n = 61)

Conventional 3D-mapping (n = 61)

P value

Age, years

64.8 ± 11.9

67.0 (59.0–74.0)

64.8 ± 11.2

64.0 (58.0–73.0)

64.9 ± 12.7

68.0 (59.0–74.0)

0.652

Male sex, n (%)

113 (92.6)

57 (93.4)

56 (91.8)

1.000

BMI, kg/m2

28.0 ± 4.3

27.0 (25.0–30.0)

28.3 ± 3.9

28.0 (26.0–30.0)

27.8 ± 4.7

27.0 (25.0–29.0)

0.149

Cardiomyopathy type, n (%)

   

0.852

Ischemic

76 (62.3)

37 (60.7)

39 (63.9)

 

Non-ischemic

46 (37.7)

24 (39.3)

22 (36.1)

 

Art. hypertension, n (%)

84 (68.9)

43 (70.5)

41 (67.2)

0.845

Diabetes, n (%)

26 (21.3)

13 (21.3)

13 (21.3)

1.000

Chronic kidney disease,

n (%)

53 (43.4)

22 (36.1)

31 (50.8)

0.144

Atrial fibrillation, n (%)

48 (39.3)

26 (42.6)

22 (36.1)

0.578

OAK, n (%)

58 (47.5)

32 (52.5)

26 (42.6)

0.365

LV-EF, %

34.8 ± 13.4

35.0 (23.5–44.8)

35.7 ± 11.6

35.0 (25.0–40.0)

33.8 ± 14.9

35.0 (20.0–45.0)

0.236

Syncope, n (%)

26 (21.3)

13 (21.3)

13 (21.3)

1.000

ICD, n (%)

106 (86.9)

57 (93.4)

49 (80.3)

0.058

AAD before Ablation, n (%)

113 (92.6)

56 (91.8)

57 (93.4)

1.000

  Betablockers

88 (72.1)

35 (57.4)

53 (86.9)

0.001

  Amiodarone

59 (48.4)

30 (49.2)

29 (47.5)

1.000

  1. Unless noted, values are mean ± standard deviation / median (interquartile range) or n (percent). P value < 0.05 is considered significant.
  2. AAD indicates antiarrhythmic drug therapy; Art., arterial; BMI, body mass index; ICD, implantable cardioverter-defibrillator; LV-EF, left ventricular ejection fraction; OAK, oral anticoagulation; 3D, three-dimensional.
Back to article page